臨床外科76巻13号

2021年12月発行

特集 Conversion surgeryアップデート

総論

Conversion surgeryのために外科医が知っておきたいリキッドバイオプシーとゲノム検査の最新知識

著者： 小林信¹ 中村能章² 後藤田直人¹ 吉野孝之²

所属機関： ¹国立がん研究センター東病院肝胆膵外科 ²国立がん研究センター東病院消化管内科

ページ範囲：P.1456 - P.1462

文献概要

【ポイント】
◆ctDNAによるゲノム解析は，組織生検の侵襲性や空間的・時間的不均一性などを克服し，腫瘍の全体像を包括的に把握しうる．
◆ctDNAを用いた臨床開発としては，切除不能例に加え，切除例でも微小残存病変の検出や治療などが進んでいる．
◆ctDNA検査は，conversion surgeryの適応や時期の最適化に寄与する可能性がある．

参考文献

1）血中循環腫瘍DNAを用いたがんゲノムプロファイリング検査の適正使用に関する政策提言，2021〔http://www.jsco.or.jp/jpn/user_data/upload/File/20210120.pdf〕（Accessed 27 April, 2021）

2）Campbell PJ, Getz G, Korbel JO, et al：Pan-cancer analysis of whole genomes. Nature 578：82-93, 2020

3）Corcoran RB, Chabner BA：Application of Cell-free DNA Analysis to Cancer Treatment. N Engl J Med 379：1754-1765, 2018

4）Nakamura Y, Taniguchi H, Ikeda M, et al：Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer：SCRUM-Japan GI-SCREEN and GOZILA studies. Nat Med 2020

5）Tie J, Kinde I, Wang Y, et al：Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol 26：1715-1722, 2015

6）Jones RP, Pugh SA, Graham J, et al：Circulating tumour DNA as a biomarker in resectable and irresectable stage Ⅳ colorectal cancer；a systematic review and meta-analysis. Eur J Cancer 144：368-381, 2021

7）Siravegna G, Mussolin B, Buscarino M, et al：Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 21：795-801, 2015

8）Siena S, Sartore-Bianchi A, Garcia-Carbonero R, et al：Dynamic molecular analysis and clinical correlates of tumor evolution within a phase Ⅱ trial of panitumumab-based therapy in metastatic colorectal cancer. Ann Oncol 29：119-126, 2018

9）Parikh AR, Leshchiner I, Elagina L, et al：Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med 25：1415-1421, 2019

10）Reinert T, Henriksen TV, Christensen E, et al：Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages Ⅰ to Ⅲ Colorectal Cancer. JAMA Oncol 2019

11）Tie J, Cohen JD, Wang Y, et al：Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage Ⅲ Colon Cancer. JAMA Oncol 2019

12）血中循環腫瘍DNA陽性の治癒切除後結腸・直腸がん患者を対象としたFTD/TPI療法とプラセボとを比較する無作為化二重盲検第Ⅲ相試験，2020〔https://www.clinicaltrials.jp/cti-user/trial/ShowDirect.jsp?japicId=JapicCTI-205363＆language=ja〕（Accessed 19 March, 2021）

13）Lee B, Lipton L, Cohen J, et al：Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. Ann Oncol 30：1472-1478, 2019

14）Conroy T, Desseigne F, Ychou M, et al：FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364：1817-1825, 2011

15）Von Hoff DD, Ervin T, Arena FP, et al：Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369：1691-703, 2013

16）Ueno H, Ikeda M, Ueno M, et al：Phase Ⅰ/Ⅱ study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 77：595-603, 2016

17）Ozaka M, Ishii H, Sato T, et al：A phase Ⅱ study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 81：1017-1023, 2018

18）Kobayashi S, Nakamura Y, Taniguchi H, et al：Impact of Preoperative Circulating Tumor DNA Status on Survival Outcomes After Hepatectomy for Resectable Colorectal Liver Metastases. Ann Surg Oncol 28：4744-4755, 2021

19）Multi-center clinical trial for personalized perioperative chemotherapy based on genetic alteration status for resectable oligometastases from colorectal cancer, 2020〔https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000048502〕（Accessed 19th November, 2020）

20）Ychou M, Rivoire M, Thezenas S, et al：Induction chemotherapy（CT）with FOLFIRINOX or FOLFOX/FOLFIRI, plus cetuximab（CET）or bevacizumab（BEV）（by RAS status）, in patients（pts）with primarily unresectable colorectal liver metastases（CRLM）：Results of the randomized UNICANCER PRODIGE 14-ACCORD 21（METHEP-2）trial. J Clin Oncol 36：3535-, 2018

21）Bidard FC, Kiavue N, Ychou M, et al：Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer：A Prospective Ancillary Study to the Unicancer Prodige-14 Trial. Cells 8：516, 2019

22）Yin L, Pu N, Thompson E, et al：Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis. Clin Cancer Res 27：740-748, 2021

23）Bando H, Kagawa Y, Kato T, et al：A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer. Br J Cancer 120：982-986, 2019